[A Case of Unresectable Advanced Gastric Cancer with Pathological Complete Response to SOX plus Nivolumab Therapy].

Q4 Medicine
Keisuke Yasuda, Naoki Urakawa, Ryuichiro Sawada, Taro Ikeda, Yasufumi Koterazawa, Takeaki Aoki, Hitoshi Harada, Yasunori Otowa, Hironobu Goto, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji
{"title":"[A Case of Unresectable Advanced Gastric Cancer with Pathological Complete Response to SOX plus Nivolumab Therapy].","authors":"Keisuke Yasuda, Naoki Urakawa, Ryuichiro Sawada, Taro Ikeda, Yasufumi Koterazawa, Takeaki Aoki, Hitoshi Harada, Yasunori Otowa, Hironobu Goto, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The patient was a 79-year-old male diagnosed with gastric cancer with lung metastasis(cT3N2M1[PUL], cStage ⅣB)and sigmoid colon cancer(cT3N0M0, cStage Ⅱa). He underwent systemic chemotherapy with the SOX plus nivolumab regimen for unresectable advanced gastric cancer. Six months after the initiation of chemotherapy(9 courses), the primary tumor and lymph node metastases in the lesser curvature and suprapancreatic margin had shrunk, and the lung metastases had disappeared. However, chemotherapy was discontinued because of the development of immune-related interstitial pneumonia, and steroid therapy was initiated. Nine months after the initiation of chemotherapy, the tumor shrinkage rate remained constant and interstitial pneumonia improved; however, the patient was referred to our hospital for surgical treatment for gastric stenosis. A laparoscopic distal gastrectomy was performed for gastric cancer. Histopathological findings revealed no residual cancer cells in the primary tumor or lymph nodes, and the histological response was Grade 3. The patient remained recurrence-free for 10 months after the surgery. SOX plus nivolumab therapy for unresectable advanced gastric cancer is expected to have a high tumor-shrinkage effect, and combining it with conversion surgery may lead to an improved long-term prognosis.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 8","pages":"601-603"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Cancer and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The patient was a 79-year-old male diagnosed with gastric cancer with lung metastasis(cT3N2M1[PUL], cStage ⅣB)and sigmoid colon cancer(cT3N0M0, cStage Ⅱa). He underwent systemic chemotherapy with the SOX plus nivolumab regimen for unresectable advanced gastric cancer. Six months after the initiation of chemotherapy(9 courses), the primary tumor and lymph node metastases in the lesser curvature and suprapancreatic margin had shrunk, and the lung metastases had disappeared. However, chemotherapy was discontinued because of the development of immune-related interstitial pneumonia, and steroid therapy was initiated. Nine months after the initiation of chemotherapy, the tumor shrinkage rate remained constant and interstitial pneumonia improved; however, the patient was referred to our hospital for surgical treatment for gastric stenosis. A laparoscopic distal gastrectomy was performed for gastric cancer. Histopathological findings revealed no residual cancer cells in the primary tumor or lymph nodes, and the histological response was Grade 3. The patient remained recurrence-free for 10 months after the surgery. SOX plus nivolumab therapy for unresectable advanced gastric cancer is expected to have a high tumor-shrinkage effect, and combining it with conversion surgery may lead to an improved long-term prognosis.

[1例不可切除的晚期胃癌对SOX联合纳武单抗治疗病理完全缓解]。
患者为男性,79岁,诊断为胃癌合并肺转移(cT3N2M1[PUL], cStageⅣB)和乙状结肠癌(cT3N0M0, cStageⅡa)。他接受了SOX加纳武单抗方案的全身化疗,治疗不可切除的晚期胃癌。化疗开始6个月(9个疗程)后,原发肿瘤及小弯及胰上缘淋巴结转移缩小,肺转移灶消失。然而,由于免疫相关性间质性肺炎的发展,化疗停止,并开始类固醇治疗。化疗开始9个月后,肿瘤缩小率保持不变,间质性肺炎好转;然而,该患者因胃狭窄被转介至我院接受手术治疗。腹腔镜下胃癌远端切除术。组织病理学结果显示原发肿瘤或淋巴结中未发现残留癌细胞,组织学反应为3级。术后10个月患者无复发。SOX联合纳武单抗治疗不可切除的晚期胃癌有望具有较高的肿瘤缩小效果,并与转换手术相结合可能改善长期预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
337
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信